Conventional wisdom in oncology is that drug resistance is a stable and heritable phenotype
due largely to cancer cell acquisition of genetic alterations. Thus, most cancer agents are …

The antitumor mechanisms of sorafenib in hepatocellular carcinoma (HCC) may involve
complex interactions of signaling pathways in cancer cells and the tumor microenvironment …

Acquired evasive resistance is a major limitation of hepatocellular carcinoma (HCC)
treatment with the tyrosine kinase inhibitor (TKI) sorafenib. Recent findings suggest that …

Sorafenib is a multikinase inhibitor capable of facilitating apoptosis, mitigating angiogenesis
and suppressing tumor cell proliferation. In late-stage hepatocellular carcinoma (HCC) …

Acquired resistance to antiangiogenic drugs, such as sorafenib, is a major clinical problem.
We studied development of a resistance to sorafenib in new preclinical models of human …

Sorafenib leads to a survival benefit in patients with advanced hepatocellular carcinoma but
its use is hampered by the occurrence of drug resistance. To investigate the molecular …

Sorafenib, the unique drug as first-line treatment for advanced hepatocellular carcinoma
(HCC), has opened a window of hope after searching for effective agents to combat HCC for …

Liver cancer is one of the most common and devastating causes of cancer-related deaths
worldwide. Hepatocellular carcinoma (HCC) accounts for approximately 90% of primary liver …

Sorafenib, an orally-available kinase inhibitor, is the only standard clinical treatment against
advanced hepatocellular carcinoma. However, development of resistance to sorafenib has …

It is disappointing that only a few patients with hepatocellular carcinoma (HCC) obtain a
significant survival benefit from the sorafenib treatment, which is currently regarded as a first …